Benitec locks in US and UK patents for RNAi tech
05 June, 2003 by Pete YoungGene silencing company Benitec has locked in place US and UK patents for the technology which underpins a recent global licensing pact signed by the Brisbane biotech.
Bionomics scores with new appointment
05 June, 2003 by Melissa TrudingerFormer Merck Research Laboratories director of neuropharmacology Dr Mark Varney has joined Adelaide company Bionomics as VP of drug discovery, where he will lead the company's epilepsy and central nervous system drug discovery program.
Novogen drug results released at ASCO meeting
04 June, 2003 by Melissa TrudingerNovogen subsidiary Marshall Edwards' anti-cancer drug phenoxodiol has featured at the American Society of Clinical Oncology meeting in Chicago this week, with Yale researchers presenting data demonstrating that the compound is added to low levels of standard chemotherapy agent cisplatin, the size of human ovarian cancer tumours in animal models by up to 75 per cent.
Starpharma in trans-Tasman dendrimer alliance
04 June, 2003 by Melissa TrudingerStarpharma has formed an alliance with New Zealand Crown Research Institute company Industrial Research Limited (IRL) to develop carbohydrate functionalised dendrimers, in a five-year collaboration supported to the tune of $AUD5.1 million by the New Zealand government.
$9m in ARC grants released
03 June, 2003 by Melissa TrudingerSome of Australia's best-known biotechs -- including Biota, Gradipore, Amrad, Proteome Systems, Nanomics, Starpharma and PanVax -- will benefit from the latest round of Australian Research Council linkage grants.
Peplin raises $3.5m, plans to broaden pipeline
02 June, 2003 by Melissa TrudingerQueensland-based Peplin Biotech has raised $AUD3.5 million before expenses through the placement of five million shares at $AUD0.70 to domestic and international institutional investors.
Eiffel names CEO as executive director
02 June, 2003 by Melissa TrudingerEiffel Technologies' CEO Christine Cussen has joined the company's board as an executive director.
New report recommends national genetic advisory body
30 May, 2003 by Melissa TrudingerThe report on the protection of human genetic information released yesterday by the Australian Law Reform Commission and the NHMRC's Australian Health Ethics Committee (AHEC) was the most comprehensive review on the laws covering genetic information and privacy in the world, according to Prof Don Chalmers, dean of law at the University of Tasmania.
Childbirth tea may stop caterpillar scourge
30 May, 2003 by Jeremy TorrUniversity of Queensland and Institute for Molecular Biology researcher Prof David Craik has isolated a protein that could help stop the advance of the voracious Helicoverpa caterpillar through our agricultural backyard.
Gradipore trade halted as director calls for board revamp
29 May, 2003 by Iain ScottTrading in shares of Sydney-based company Gradipore were halted this afternoon after one of the company's directors sought to call a shareholder meeting to remove four directors from the board and elect two new ones.
Sirtex back to business after failed takeover bid
29 May, 2003 by Jeremy TorrWith Cephalon and its takeover retiring behind the sidelines - officially, at least -- Sirtex is back to business, according to founder and CEO Bruce Gray. With a changed team if necessary.
Peptech's arthritis dAb comes up trumps
28 May, 2003 by Graeme O'NeillSydney biotech Peptech has reported "outstanding" results from a cut-down experimental antibody molecule as potential treatment for the crippling autoimmune disorder, rheumatoid arthritis.
Mayne eases the pain with a $25m suit against Pan
28 May, 2003 by Jeremy TorrHealthcare giant Mayne has filed a Victorian Supreme Court claim against troubled manufacturer Pan Pharmaceuticals, following an estimated $AUD25 million-plus loss of revenue and recall costs.
Progen scores Alchemia fallout
28 May, 2003 by Jeremy TorrDiscovery biotech Progen has snapped up one of the casualties of last month's Alchemia implosion, in the form of business development manager Dr Darren Schliebs, previously employed at Alchemia's San Francisco office.
Solbec trades gold stakes to boost biotech
28 May, 2003 by Jeremy TorrAnti-cancer biotech Solbec Pharmaceuticals has committed to abandoning its mining roots with a penultimate sell-off of several mineral leases, and a pledge to sell the remainder soon.
